Antibody Egfr Interaction
Antibody Egfr Interaction - Related Videos
05:16
Mass Photometry to Study Antigen-Antibody Interactions on a Single-Molecule Level
0 Views •
2025
In this video, we demonstrate the use of mass photometry to study antigen-antibody interactions in a flow chamber. The focused light scatters differently based on the mass of the molecules. A detector collects the scattered light and generates the interference pattern as spots of varied intensities, which correlate with the molecular masses.
03:46
Butyl-Dependant Hydrophobic Interaction Liquid Chromatography: A Technique to Characterize Antibody-Drug Conjugates Based on Hydrophobic Interactions
0 Views •
2025
This video demonstrates the hydrophobic interaction liquid chromatography-based characterization of antibody-drug conjugates. Using a butyl ligand-based chromatography column, the antibody-drug conjugates are characterized via hydrophobic interactions with the ligand.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
01:10
Antibody Structure
0 Views •
2019
Overview Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding. The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains Antibodies consist of four polypeptide chains: two identical heavy...
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
FAQs
Binding to the extracellular region can reduce EGFR signaling through several distinct routes. An antibody may prevent a ligand from engaging the receptor, interfere with receptor dimerization, or encourage receptor internalization. Each route limits transmission to downstream kinase pathways, so the resulting decrease in signaling can affect cellular growth, survival, or differentiation.
Preventing receptor dimerization interrupts a step associated with EGFR signaling through downstream kinase pathways. This mechanism differs from simply blocking ligand engagement because the antibody limits receptor pairing itself. Reduced dimerization can therefore weaken signal propagation and diminish cellular responses related to growth, survival, and differentiation.
Antibody-mediated EGFR inhibition can be understood through three outcomes: ligand-binding blockade, prevention of receptor dimerization, and receptor internalization. The first limits receptor engagement, the second restricts receptor pairing, and the third promotes removal of receptor from the cell surface. Distinguishing these outcomes clarifies how binding is translated into reduced kinase signaling.
Genetic interpretation should examine EGFR mutations, gene amplification, and altered expression. These features can change how abnormal EGFR signaling relates to cellular behavior and how cells respond to an antibody-based intervention. Considering all three prevents the interaction from being viewed only as a binding event and connects receptor biology with disease-associated phenotypes.
Studying Antibody Egfr Interaction can support biomarker development by linking antibody effects to the genetic state of EGFR. If mutations, amplification, or altered expression are associated with particular cellular behaviors or treatment responses, those features may help identify biologically meaningful groups for analysis. The value comes from connecting molecular measurements with observed response patterns.
Researchers can use these analyses to relate receptor-level inhibition to disease research and targeted therapy design. The key outcome is not only whether an antibody binds, but whether that interaction corresponds to reduced downstream kinase signaling and altered cellular behavior. This relationship can guide interpretation of treatment response in cancers driven by abnormal EGFR signaling.